ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial-anastrozole is superior to tamoxifen as adjuvant treatment in postmenopausal women with early breast cancer.

被引：0

作者：

Bianco, R ^{[1
]}

机构：

[1] Univ Naples Federico II, Naples, Italy

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

632

引用

页码：S155 / S155

页数：1

共 50 条

[11] The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer
Howell, Anthony
REVIEWS ON RECENT CLINICAL TRIALS, 2006, 1 (03) : 207 - 215
[12] Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
Houghton, J
Baum, M
EUROPEAN JOURNAL OF CANCER, 1998, 34 : S83 - S83
[13] Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial (vol 359, pg 2131, 2002)
Fodor, J
Borrego, MR
LANCET, 2002, 360 (9344) : 1520 - 1520
[14] Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
Baum, M
Houghton, J
EUROPEAN JOURNAL OF CANCER, 1998, 34 : S39 - S39
[15] Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer
Bago-Horvath, Zsuzsanna
Rudas, Margaretha
Dubsky, Peter
Jakesz, Raimund
Singer, Christian F.
Kemmerling, Ralf
Greil, Richard
Jelen, Andrea
Boehm, Gerhard
Jasarevic, Zerina
Haid, Anton
Gruber, Christine
Poestlberger, Sabine
Filipits, Martin
Gnant, Michael
CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7828 - 7834
[16] Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial
Duffy, SRG
Taylor, L
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (06) : 1921 - 1927
[17] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A
Cuzick, J
Baum, M
Buzdar, A
Dowsett, M
Forbes, JF
Hoctin-Boes, G
Houghton, I
Locker, GY
Tobias, JS
LANCET, 2005, 365 (9453) : 60 - 62
[18] The ATAC ('Arimidex', Tamoxifen, alone or in combination) early breast cancer trial in postmenopausal patients: endometrial sub-protocol results
Duffy, S
Jackson, T
INTERNATIONAL JOURNAL OF CANCER, 2002, : 137 - 138
[19] 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview
Buzdar, AU
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5) : 399 - 403
[20] Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: A US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial
Locker, Gershon Y.
Mansel, Robert
Cella, David
Dobrez, Deborah
Sorensen, Sonja
Gandhi, Sanjay K.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (02) : 229 - 238

← 1 2 3 4 5 →